Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 28, 2019.
September 27, 2019 at 07:00 am IST
Share
From June 28, 2019 to June 30, 2019, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for KRW 0 million under the buyback announced on June 28, 2019.
HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.